CRBU CARIBOU BIOSCIENCES INC

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:

  • 2025 Truist Securities BioPharma Symposium, New York

    November 6, 2025
  • 8th Annual Evercore Healthcare Conference, Coral Gables, FL

    December 2, 2025 with fireside chat at 8:45-9:05 AM ET





For more information and links to webcasts, please visit the page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.

Caribou Biosciences, Inc. contact:

Peggy Vorwald, PhD





EN
03/11/2025

Underlying

CRBUCARIBOU BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CARIBOU BIOSCIENCES INC

 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences to Participate in Upcoming Investor Conferences BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: Citi 2026 Virtual Oncology Leadership Summit, VirtualFebruary 19, 2026, with a fireside chat at 10:45 AM ET Leerink Global Healthcare Conference, Miami, FLMarch 10, 2026, with a fireside chat at 8:00 AM ET For more information and link to the Leerink webcast, please visit ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 ...

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR® Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy and durability that is on par with autologous CAR-T cell therapy in 2L LBCL patients CB-011 CaMMouflage phase 1 translational and clinical data correlate CAR-T cell expansion with deep, durable responses and support the regimen selected for dose expansion BERKELE...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 202...

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will host an expert physician panel discussion during an ancillary event at the 67th American Society of Hematology (ASH) Annual Mee...

December 1, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Reports Third Quarter 2025 Financial Results and P...

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for LBCLCB-011 CaMMouflage phase 1 data demonstrate deep, durable responses and manageable safety, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for r/r multiple myeloma$159.2 million in cash, cash equivalents, and marketable securities as of...

November 12, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences to Participate in Upcoming Investor Conferences BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: 2025 Truist Securities BioPharma Symposium, New YorkNovember 6, 2025 8th Annual Evercore Healthcare Conference, Coral Gables, FLDecember 2, 2025 with fireside chat at 8:45-9:05 AM ET For more information and links to webcasts, please visit the page on Caribou’s website. W...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch